On April 1, 2022, the Food and Drug Administration approved axicabtagene ciloleucel (Yescarta, Kite Pharma, Inc.) for adult patients with large B-cell lymphoma (LBCL) that is refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoimmunotherapy. It is not indicated for the treatment of patients with primary central nervous system lymphoma. Approval was
Natural killer (NK) cells derived from cord blood that were activated and complexed with a CD30/CD16A bispecific antibody elicited an 89 percent overall response rate in patients with relapsed or refractory CD30+ lymphoma, according to results from a phase I/II clinical trial presented at the AACR Annual Meeting 2022, held April 8-13. “We were favorably surprised by the
One of the primary anomalies of SARS-CoV-2 infection lies in our gut. Our intestine spans hundreds of feet in surface area and is rich with ACE2 receptors—the key receptors by which SARS-CoV-2 infects cells. Yet, most of the identifying SARS-CoV-2 symptoms are isolated to respiratory illnesses. Why is it that even though the gut is
A MRNA VACCINE WAS COMBINED WITH CAR T CELLS THAT TARGET TUMOR CELLS EXPRESSING THE CLDN6 ANTIGEN A new chimeric antigen receptor (CAR) T-cell product had an acceptable safety profile and showed early signs of efficacy as a monotherapy and in combination with an mRNA vaccine in patients with solid tumors, according to preliminary data
Antibiotics are ineffective treatment for viral syndromes, including COVID-19. Was characterized antibiotic prescribing in older adults with outpatient COVID-19 visits to identify opportunities to improve prescribing practices. Were used 100% Medicare carrier claims and Part D event files to identify beneficiaries with a COVID-19 outpatient visit and associated antibiotic prescriptions. We included beneficiaries aged 65
In June 2020, preliminary results for the Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial conducted in the UK indicated benefit from dexamethasone in severely ill hospitalized patients with COVID-19 but potential harm in those not requiring oxygen. In October 2020, the National Institutes of Health (NIH) issued COVID-19 treatment guidelines advising against systemic corticosteroid use
CD19 CAR T-cell therapy is effective at achieving durable remission for relapsed/refractory ALL across cytogenetic risk groups. CD19 CAR T-cell treatment results for patients with high-risk cytogenetics including Ph+, Ph-like, and KMT2A-rearranged ALL are encouraging. Chimeric antigen receptor (CAR) T-cell therapy can induce durable remissions of relapsed/refractory B-acute lymphoblastic leukemia (ALL). However, case reports suggested differential
Emerging studies have increasingly recognized Covid-19 as an inflammatory disease. Brain shrinkage, brain-blood barrier disruptions and neurodegeneration seem to emerge as an inflammatory consequence of acute infection that for some progresses into Long Covid. Cognitive impairments are consistently reported as one of the most persistent and some of the more impairing symptoms of Long Covid.
Stanford researchers have been working on gene therapies for epidermolysis bullosa, or “butterfly disease,” for over a decade. A new gel helped wounds heal and stay healed in a clinical trial. A gene therapy gel applied to the wounds of nine people — three of whom were children — with the blistering skin disease epidermolysis
Yale researchers have identified a particular immune response pathway that leads to severe illness and death in people infected by the SARS-CoV-2 virus. The study was published as a preprint submission on bioRxiv. Researchers have known that once the COVID-19 virus infects the lungs it can trigger what has been called a “cytokine storm,” or an
